• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Beta Bionics Announces the Appointment of Martha Goldberg Aronson as Chair of Its Board of Directors

    2/9/21 4:01:00 PM ET
    $CSII
    $MEI
    $CNMD
    Medical/Dental Instruments
    Health Care
    Electrical Products
    Technology
    Get the next $CSII alert in real time by email

    CONCORD, Mass.--(BUSINESS WIRE)--Beta Bionics, Inc., a medical technology company focused on the design, development, and commercialization of the iLet® bionic pancreas system, today announced the appointment of Martha Goldberg Aronson as Chair of its Board of Directors, effective immediately.

    Ms. Aronson, who joined the Beta Bionics Board as a Director in February of 2020, succeeds Ed Damiano, President and Chief Executive Officer of Beta Bionics, who has served as Chair since inception of the company in 2015. Dr. Damiano will remain a member of the Board while continuing to serve in his roles as President and Chief Executive Officer of Beta Bionics.

    “On behalf of the Board, I am pleased to welcome Martha into the role of Chair,” commented Ed Damiano, President and Chief Executive Officer. “We look forward to continuing to benefit from Martha’s leadership, knowledge, and healthcare expertise as we seek to fulfill our mission to bring the iLet to as many people living with diabetes as possible. It has been a great honor to have served as Chair of the Beta Bionics Board of Directors over the past five years, and I’m looking forward to continuing to work closely with Martha and the Board.”

    “I am honored to take on the role of Chair of the Beta Bionics Board of Directors as we continue to grow the organization and deliver on the Company’s mission. Working alongside Ed and our fellow directors, we will not only strive toward this mission, but also serve our varied stakeholders as a public benefit corporation and Certified B Corp.” said Ms. Aronson.

    Ms. Aronson brings more than two decades of leadership experience in publicly traded companies in the med-tech industry. She currently serves as Lead Independent Director on the board of Conmed Corporation (NYSE: CNMD) and on the board of Cardiovascular Systems Inc. (NASDAQ: CSII). Her previous board roles included serving as a director at Hutchinson Technology, Inc. (NASDAQ: HTCH) and Methode Electronics (NYSE: MEI). She was the executive vice president and president of Global Healthcare at Ecolab, Inc., where she was responsible for the global healthcare business with a specific focus on products and programs for infection prevention. Prior to that, Ms. Aronson served as senior vice president and president, North America, at Hill-Rom Holdings, where she was responsible for a $1-billion hospital equipment business. Ms. Aronson also spent 18 years in various general management and executive roles at Medtronic, Inc., both in the U.S. and internationally.

    Ms. Aronson received her Master of Business Administration from Harvard Business School and a Bachelor of Arts in Economics from Wellesley College, graduating magna cum laude and Phi Beta Kappa.

    About Beta Bionics

    Beta Bionics® is a medical device company focused on the design, development, and commercialization of its iLet bionic pancreas system, which has the potential to be a revolutionary solution for people with diabetes on intensive insulin therapy. The iLet bionic pancreas is designed to use adaptive control algorithms, together with continuous glucose monitoring and pump technology, to autonomously compute and administer all doses of either insulin or glucagon or both and mimic the body’s natural ability to maintain tight glycemic control.

    The iLet bionic pancreas features an intuitive user interface, which only requires the input of a patient’s body weight to initiate dosing. The iLet’s simple user interface, together with its automated, adaptive control algorithms, is designed to eliminate many of the cumbersome tasks of diabetes management in order to decrease the cognitive and emotional burden of living with diabetes.

    Beta Bionics is a for-profit, public benefit corporation and Certified B Corporation™. Since its founding in 2015, its mission has been to help improve health outcomes and the quality of life of all children and adults living with diabetes and other conditions of glycemic dysregulation.

    Beta Bionics operates in Massachusetts and California. For further information, please visit www.betabionics.com or follow Beta Bionics Facebook, YouTube, Instagram, LinkedIn and Twitter @BetaBionics.

    Get the next $CSII alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CSII
    $MEI
    $CNMD

    CompanyDatePrice TargetRatingAnalyst
    CONMED Corporation
    $CNMD
    6/12/2025Buy → Hold
    Needham
    CONMED Corporation
    $CNMD
    4/28/2025$55.00Buy → Hold
    Stifel
    Methode Electronics Inc.
    $MEI
    2/25/2025Neutral → Buy
    Sidoti
    CONMED Corporation
    $CNMD
    2/6/2025$85.00 → $70.00Overweight → Neutral
    Analyst
    Methode Electronics Inc.
    $MEI
    4/9/2024$12.00Hold
    Jefferies
    Methode Electronics Inc.
    $MEI
    3/7/2024$17.00Buy → Neutral
    Sidoti
    CONMED Corporation
    $CNMD
    2/1/2024$119.00 → $129.00Buy
    Needham
    CONMED Corporation
    $CNMD
    5/22/2023$140.00Buy
    CL King
    More analyst ratings

    $CSII
    $MEI
    $CNMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP Global Automotive Business Ullrich Lars bought $101,390 worth of shares (15,150 units at $6.69) (SEC Form 4)

    4 - METHODE ELECTRONICS INC (0000065270) (Issuer)

    3/18/25 6:16:41 PM ET
    $MEI
    Electrical Products
    Technology

    CEO and President Degaynor Jonathan B bought $211,357 worth of shares (32,733 units at $6.46) (SEC Form 4)

    4 - METHODE ELECTRONICS INC (0000065270) (Issuer)

    3/12/25 7:00:04 AM ET
    $MEI
    Electrical Products
    Technology

    Director Lindsey Mary A bought $100,108 worth of shares (8,800 units at $11.38), increasing direct ownership by 51% to 25,970 units (SEC Form 4)

    4 - METHODE ELECTRONICS INC (0000065270) (Issuer)

    9/25/24 5:00:04 PM ET
    $MEI
    Electrical Products
    Technology

    $CSII
    $MEI
    $CNMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Methode Electronics to Release First Quarter Fiscal 2026 Results on Wednesday, September 3, 2025

    CHICAGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Methode Electronics, Inc. (NYSE:MEI), a leading global supplier of custom-engineered solutions for user interface, lighting system and power distribution applications, announced it will release its first quarter fiscal 2026 results for the period ended August 2, 2025, on Wednesday, September 3, 2025, after market close. The company will conduct a conference call and webcast the following day, Thursday, September 4, 2025, at 10:00 a.m. CDT to review financial and operational highlights led by its President and Chief Executive Officer, Jon DeGaynor, and Chief Financial Officer, Laura Kowalchik. To participate in the conference call, please dial 88

    8/21/25 4:05:00 PM ET
    $MEI
    Electrical Products
    Technology

    CONMED Corporation Announces Quarterly Cash Dividend

    CONMED Corporation (NYSE:CNMD) today announced that its Board of Directors declared a quarterly cash dividend of $0.20 per share on August 7, 2025, payable on October 3, 2025, to all shareholders of record as of September 15, 2025. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com. Forward-Looking Statements This press release may contain forward-looking statements based

    8/8/25 7:00:00 AM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Methode Electronics to Present at the J.P. Morgan Auto Conference

    CHICAGO, Ill., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Methode Electronics, Inc. (NYSE:MEI), a leading global supplier of custom-engineered solutions for user interface, lighting, and power distribution applications, will present at the J.P. Morgan Auto Conference on Tuesday, August 12th at 12:40 p.m. EDT. A simultaneous webcast can be accessed on the company's website, www.methode.com, by selecting the Investors page. The webcast will also be archived on the same Investors page. About Methode Electronics, Inc.Methode Electronics, Inc. (NYSE:MEI) is a leading global supplier of custom-engineered solutions with sales, engineering and manufacturing locations in North America, Europe, Middle East

    8/5/25 4:05:00 PM ET
    $MEI
    Electrical Products
    Technology

    $CSII
    $MEI
    $CNMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CONMED downgraded by Needham

    Needham downgraded CONMED from Buy to Hold

    6/12/25 7:52:09 AM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CONMED downgraded by Stifel with a new price target

    Stifel downgraded CONMED from Buy to Hold and set a new price target of $55.00

    4/28/25 8:32:52 AM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Methode Electronics upgraded by Sidoti

    Sidoti upgraded Methode Electronics from Neutral to Buy

    2/25/25 8:43:24 AM ET
    $MEI
    Electrical Products
    Technology

    $CSII
    $MEI
    $CNMD
    SEC Filings

    View All

    SEC Form DEFA14A filed by Methode Electronics Inc.

    DEFA14A - METHODE ELECTRONICS INC (0000065270) (Filer)

    8/12/25 5:05:03 PM ET
    $MEI
    Electrical Products
    Technology

    Methode Electronics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - METHODE ELECTRONICS INC (0000065270) (Filer)

    8/12/25 5:00:31 PM ET
    $MEI
    Electrical Products
    Technology

    CONMED Corporation filed SEC Form 8-K: Other Events

    8-K - CONMED Corp (0000816956) (Filer)

    8/8/25 2:17:07 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CSII
    $MEI
    $CNMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and President Degaynor Jonathan B was granted 328,520 shares, increasing direct ownership by 305% to 436,225 units (SEC Form 4)

    4 - METHODE ELECTRONICS INC (0000065270) (Issuer)

    8/12/25 6:00:07 PM ET
    $MEI
    Electrical Products
    Technology

    CPO & EHS Officer Erwin John Thomas was granted 31,324 shares, increasing direct ownership by 94% to 64,480 units (SEC Form 4)

    4 - METHODE ELECTRONICS INC (0000065270) (Issuer)

    8/12/25 6:00:10 PM ET
    $MEI
    Electrical Products
    Technology

    General Counsel Vyverberg Kerry A. was granted 29,595 shares, increasing direct ownership by 238% to 42,032 units (SEC Form 4)

    4 - METHODE ELECTRONICS INC (0000065270) (Issuer)

    8/12/25 6:00:09 PM ET
    $MEI
    Electrical Products
    Technology

    $CSII
    $MEI
    $CNMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by CONMED Corporation

    SC 13G/A - CONMED Corp (0000816956) (Subject)

    11/13/24 4:22:22 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Methode Electronics Inc.

    SC 13G/A - METHODE ELECTRONICS INC (0000065270) (Subject)

    11/12/24 4:04:11 PM ET
    $MEI
    Electrical Products
    Technology

    Amendment: SEC Form SC 13G/A filed by CONMED Corporation

    SC 13G/A - CONMED Corp (0000816956) (Subject)

    11/12/24 12:53:28 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CSII
    $MEI
    $CNMD
    Financials

    Live finance-specific insights

    View All

    Methode Electronics to Release First Quarter Fiscal 2026 Results on Wednesday, September 3, 2025

    CHICAGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Methode Electronics, Inc. (NYSE:MEI), a leading global supplier of custom-engineered solutions for user interface, lighting system and power distribution applications, announced it will release its first quarter fiscal 2026 results for the period ended August 2, 2025, on Wednesday, September 3, 2025, after market close. The company will conduct a conference call and webcast the following day, Thursday, September 4, 2025, at 10:00 a.m. CDT to review financial and operational highlights led by its President and Chief Executive Officer, Jon DeGaynor, and Chief Financial Officer, Laura Kowalchik. To participate in the conference call, please dial 88

    8/21/25 4:05:00 PM ET
    $MEI
    Electrical Products
    Technology

    CONMED Corporation Announces Quarterly Cash Dividend

    CONMED Corporation (NYSE:CNMD) today announced that its Board of Directors declared a quarterly cash dividend of $0.20 per share on August 7, 2025, payable on October 3, 2025, to all shareholders of record as of September 15, 2025. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com. Forward-Looking Statements This press release may contain forward-looking statements based

    8/8/25 7:00:00 AM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CONMED Corporation Announces Second Quarter 2025 Financial Results

    CONMED Corporation (NYSE:CNMD) today announced financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Highlights Sales of $342.3 million increased 3.1% year-over-year as reported and 2.9% in constant currency. Domestic revenue increased 2.8% year-over-year. International revenue increased 3.4% year-over-year as reported and 2.9% in constant currency. Diluted net earnings per share (GAAP) were $0.69, compared to diluted net earnings per share (GAAP) of $0.96 in the second quarter of 2024. Adjusted diluted net earnings per share(1) were $1.15, compared to adjusted diluted net earnings per share of $0.98 in the second quarter of 2024. "We are enco

    7/30/25 4:05:00 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CSII
    $MEI
    $CNMD
    Leadership Updates

    Live Leadership Updates

    View All

    CONMED Corporation Appoints LaVerne Council as Chair of the Board of Directors

    CONMED Corporation (NYSE:CNMD) today announced that LaVerne Council has been appointed to succeed Martha Goldberg Aronson as the new Independent Chair of its Board of Directors, effective May 21, 2025. "LaVerne's extensive experience as a global operations and information technology executive have been invaluable to CONMED, and I know that her experience will continue to serve the Board and the Company well in her new role as Chair of the Board," said Pat Beyer, President and Chief Executive Officer, CONMED. "I also want to thank Martha for her ongoing contributions to CONMED. Martha's strategic direction and steady leadership have been crucial to CONMED in her role as Chair, and her conti

    5/21/25 7:03:00 AM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Methode Electronics Appoints Brad Corrodi as Chief Strategy Officer

    CHICAGO, March 05, 2025 (GLOBE NEWSWIRE) -- Methode Electronics, Inc. (NYSE:MEI), a leading global supplier of custom-engineered solutions for user interface, lighting, and power distribution applications, announced today that Brad Corrodi has been appointed as Chief Strategy Officer (CSO) effective March 10, 2025. Mr. Corrodi joins Methode with more than 30 years of experience serving in strategic, investment, and operating roles. He will be based at the company's headquarters in Chicago, Illinois. "Brad's blend of strategy and operational experience will be a key differentiator, as we continue to reshape Methode's future," said Jon DeGaynor, President and Chief Executive Officer. "With

    3/5/25 7:00:00 AM ET
    $MEI
    Electrical Products
    Technology

    Methode Electronics Appoints Karen Keegans as Chief Human Resources Officer

    CHICAGO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Methode Electronics, Inc. (NYSE:MEI), a leading global supplier of custom-engineered solutions for user interface, lighting, and power distribution applications, announced today that Karen Keegans has been appointed as Chief Human Resources Officer (CHRO) effective February 3, 2025. Ms. Keegans succeeds Andrea Barry, who has served as CHRO since 2017. Ms. Keegans joins Methode with more than 30 years of leadership experience, serving in the capacity of CHRO for several global industrial organizations, including Fortune 500 companies, such as Rockwell Automation, Pentair, and Praxair. She will be based at the company's headquarters in Chicago, Ill

    1/30/25 4:05:00 PM ET
    $MEI
    Electrical Products
    Technology